Compare DFNS & AEMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFNS | AEMD |
|---|---|---|
| Founded | 2013 | 1984 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.9M |
| IPO Year | 2020 | 2008 |
| Metric | DFNS | AEMD |
|---|---|---|
| Price | $1.98 | $5.47 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | ★ $65.00 | $13.25 |
| AVG Volume (30 Days) | ★ 479.6K | 54.1K |
| Earning Date | 11-17-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 261.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $5,913,461.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $33.09 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.82 | $0.53 |
| 52 Week High | $335.00 | $25.66 |
| Indicator | DFNS | AEMD |
|---|---|---|
| Relative Strength Index (RSI) | 22.59 | 52.35 |
| Support Level | N/A | $4.86 |
| Resistance Level | $7.36 | $6.69 |
| Average True Range (ATR) | 0.44 | 0.39 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 0.76 | 45.61 |
T3 Defense Inc is a holding company that acquires and operates mission-critical defense businesses involved in national security programs. The company operates as a strategic platform, building a portfolio of mission-critical suppliers and technology companies. Its portfolio includes businesses involved in defense and aerospace technologies, such as AI software, unmanned aerial systems, electro-mechanical manufacturing, and motion control systems, as well as activities in technology distribution, licensing, and defense infrastructure development through joint ventures.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.